[go: up one dir, main page]

MX2014013858A - Metodo para tratar un cancer positivo de gd2. - Google Patents

Metodo para tratar un cancer positivo de gd2.

Info

Publication number
MX2014013858A
MX2014013858A MX2014013858A MX2014013858A MX2014013858A MX 2014013858 A MX2014013858 A MX 2014013858A MX 2014013858 A MX2014013858 A MX 2014013858A MX 2014013858 A MX2014013858 A MX 2014013858A MX 2014013858 A MX2014013858 A MX 2014013858A
Authority
MX
Mexico
Prior art keywords
positive cancer
treat
antibody
administering
patient
Prior art date
Application number
MX2014013858A
Other languages
English (en)
Other versions
MX377157B (es
Inventor
Hans Loibner
Manfred Schuster
Evelyne Janzek-Hawlat
Susanne Wiederkum
Bernhard Peball
Stefan Stranner
Oliver Mutschlechner
Franz Groiss
Ruth Ladenstein
Holger Lode
Original Assignee
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag
Publication of MX2014013858A publication Critical patent/MX2014013858A/es
Publication of MX377157B publication Critical patent/MX377157B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona a un método para tratar un cáncer positivo de GD2 al administrar una preparación que comprende un anticuerpo anti-GD2 a un paciente como una infusión intravenosa continua durante 24 horas por día.
MX2014013858A 2012-06-18 2012-07-31 Preparación para usarse en el tratamiento de un cáncer positivo de gd2. MX377157B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/061618 WO2013189516A1 (en) 2012-06-18 2012-06-18 Method for treating a gd2 positive cancer
PCT/EP2012/064970 WO2013189554A1 (en) 2012-06-18 2012-07-31 Method for treating a gd2 positive cancer

Publications (2)

Publication Number Publication Date
MX2014013858A true MX2014013858A (es) 2015-02-12
MX377157B MX377157B (es) 2025-03-07

Family

ID=46317406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013858A MX377157B (es) 2012-06-18 2012-07-31 Preparación para usarse en el tratamiento de un cáncer positivo de gd2.

Country Status (15)

Country Link
US (4) US10294305B2 (es)
JP (1) JP6283665B2 (es)
KR (1) KR101927118B1 (es)
CN (1) CN104487088A (es)
AP (1) AP2014008129A0 (es)
AU (1) AU2012383254B2 (es)
BR (1) BR112014031806A8 (es)
CA (1) CA2876529C (es)
EA (1) EA038188B1 (es)
HK (1) HK1203375A1 (es)
IL (1) IL235696A0 (es)
MX (1) MX377157B (es)
SG (2) SG11201408487WA (es)
WO (2) WO2013189516A1 (es)
ZA (1) ZA201407961B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
US9777068B2 (en) 2012-06-18 2017-10-03 Apeiron Biologics Ag Method for treating a GD2 positive cancer
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
EP3071220B1 (en) 2013-11-21 2019-12-25 Apeiron Biologics AG Preparations for treating a gd2 positive cancer
KR102614642B1 (ko) * 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
US10329323B2 (en) 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR20200010354A (ko) 2017-05-24 2020-01-30 팬디온 테라퓨틱스, 인코포레이티드 표적화된 면역관용
WO2019059771A2 (en) * 2017-09-21 2019-03-28 Umc Utrecht Holding B.V. ANTI-GD2 ANTIBODIES FOR THE TREATMENT OF NEUROBLASTOMA
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CN108948211B (zh) * 2018-07-24 2021-08-20 北京美康基免生物科技有限公司 一种基于靶向gd2的嵌合抗原受体及其应用
WO2020165402A1 (en) 2019-02-14 2020-08-20 Westfälische Wilhelms-Universität Münster Gd2-upregulation by ezh2 inhibition in cancer therapy
TW202110431A (zh) 2019-05-17 2021-03-16 美商癌症預防製藥股份有限公司 治療家族性腺瘤性瘜肉症之方法
MX2021014178A (es) 2019-05-20 2022-01-04 Pandion Operations Inc Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
WO2021020564A1 (ja) * 2019-08-01 2021-02-04 国立大学法人三重大学 Ｇｄ２結合性分子
WO2021108670A1 (en) * 2019-11-26 2021-06-03 University Of Utah Research Foundation Compositions and methods for upregulating hla class i on tumor cells
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
WO2022008902A1 (en) 2020-07-06 2022-01-13 Eusa Pharma (Uk) Limited Method for treating a gd2-positive cancer
US20240239916A1 (en) * 2021-07-05 2024-07-18 Trion Research Gmbh Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
EP4116330A1 (en) * 2021-07-05 2023-01-11 Trion Research GmbH Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
EP4194471A1 (en) * 2021-12-10 2023-06-14 Y-Mabs Therapeutics, Inc. Anti-gd2 administration regimen
GB202307103D0 (en) 2023-05-12 2023-06-28 Prinses Maxima Centrum Voor Kinderoncologie B V Method for detecting a GD2 positive cancer
WO2025257810A1 (en) * 2024-06-14 2025-12-18 Singh Biotechnology, Llc Suppression of neurodegenerative diseases by single domain antibody

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
KR20030074693A (ko) * 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
DE60333121D1 (de) * 2002-12-17 2010-08-05 Merck Patent Gmbh Pers 14.18, der gd2 bindet und seine fusion mit il-2
PL1706428T3 (pl) 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
AR056138A1 (es) 2005-10-21 2007-09-19 Hoffmann La Roche Procedimiento para la expresion recombinante de un polipeptido
EP1916257A1 (en) 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin GD2 peptide mimotopes for anticancer vaccination
JP5654986B2 (ja) 2008-06-30 2015-01-14 モーフオテク・インコーポレーテツド 抗ｇｄ２抗体並びにそれに関連する方法及び使用
AU2011268110B2 (en) * 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
EP2771364B1 (en) 2011-10-27 2019-05-22 Genmab A/S Production of heterodimeric proteins
US9777068B2 (en) 2012-06-18 2017-10-03 Apeiron Biologics Ag Method for treating a GD2 positive cancer
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
US9840566B2 (en) * 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
EP3071220B1 (en) 2013-11-21 2019-12-25 Apeiron Biologics AG Preparations for treating a gd2 positive cancer

Also Published As

Publication number Publication date
SG11201408487WA (en) 2015-02-27
MX377157B (es) 2025-03-07
CN104487088A (zh) 2015-04-01
WO2013189554A1 (en) 2013-12-27
HK1203375A1 (en) 2015-10-30
US10294305B2 (en) 2019-05-21
SG10201610532QA (en) 2017-02-27
US20200055953A1 (en) 2020-02-20
EA201500019A1 (ru) 2015-05-29
US20230340148A1 (en) 2023-10-26
WO2013189516A1 (en) 2013-12-27
ZA201407961B (en) 2015-10-28
AU2012383254B2 (en) 2017-12-14
US20180134801A1 (en) 2018-05-17
EA038188B1 (ru) 2021-07-21
BR112014031806A8 (pt) 2018-01-16
KR101927118B1 (ko) 2019-03-12
KR20150030650A (ko) 2015-03-20
AP2014008129A0 (en) 2014-12-31
AU2012383254A1 (en) 2014-11-20
JP2015521607A (ja) 2015-07-30
IL235696A0 (en) 2015-01-29
US11447565B2 (en) 2022-09-20
US20140170155A1 (en) 2014-06-19
CA2876529A1 (en) 2013-12-27
JP6283665B2 (ja) 2018-02-21
BR112014031806A2 (pt) 2017-08-29
CA2876529C (en) 2023-09-26

Similar Documents

Publication Publication Date Title
MX2014013858A (es) Metodo para tratar un cancer positivo de gd2.
MX361218B (es) Análogos de spliceostatina.
BR112012016879A2 (pt) Derivados de fumarato de acido graxo e seus usos
BR112017010188A2 (pt) análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer
PH12013501600A1 (en) Novel heterocyclic derivatives
PH12016500225A1 (en) Novel quinoline-substituted compound
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
ZA201505849B (en) Composition of novel carbohydrate drug for treatment of human diseases
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
IN2015DN01151A (es)
DOP2015000070A (es) Procedimientos para fabricar medicamentos útiles para tratar artritis reumatoide
MX354725B (es) Metodo de tratamiento de una enfermedad proliferativa.
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
WO2013155528A3 (en) Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels
EA201490210A1 (ru) Блокаторы потенциалзависимых натриевых каналов
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
NZ701974A (en) Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
PH12014502065A1 (en) Vesicular formulations
NZ707773A (en) Methods of treating liver diseases
IN2014DN03010A (es)
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados
BR112012006073A2 (pt) composições e métodos para tratar espasticidade.

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted